The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational challenges of the gene therapies Zynteglo for beta thalassemia and Lyfgenia ...
Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...
A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through ...
Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ...
With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...
Xmoor Pharma has established a strategic collaboration with the Translational Research Office (TRO) and University College ...
A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...
Gene therapy is a revolutionary field in modern medicine, offering transformative potential to treat and potentially cure a wide range of genetic and acquired diseases. By addressing the root cause of ...
In the big picture, matched sibling donor transplants remain the standard of care, Boelens said. But gene therapy is ...
A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers ...
Minaris will move its center for viral vector innovation to occupy space within CGT Catapult's collaborator laboratories in London and will work with CGT Catapult on the further development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback